AVITA MEDICAL INC (RCEL) Stock Analyst Ratings
USA - NASDAQ:RCEL - US05380C1027 - Common Stock
3.62 USD
-0.16 (-4.23%)
3.6 USD
-0.02 (-0.55%)
ChartMill assigns a Buy % Consensus number of 75% to RCEL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.65. This target is 111.33% above the current price.
RCEL was analyzed by 13 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about RCEL.
In the previous month the buy percentage consensus was at a similar level.
RCEL was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-17 | Lake Street | Downgrade | Buy -> Hold |
| 2025-09-15 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-11 | Lake Street | Maintains | Buy -> Buy |
| 2025-08-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-04 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-02-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-08 | Lake Street | Maintains | Buy -> Buy |
| 2024-12-24 | D. Boral Capital | Initiate | Buy |
| 2024-12-24 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-11-08 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-14 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-05-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-04-11 | BTIG | Downgrade | Buy -> Neutral |
| 2024-02-23 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-02-23 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-01-19 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2023-11-21 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-11-10 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-10-19 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
AVITA MEDICAL INC / RCEL FAQ
What is the price target for RCEL stock?
13 analysts have analysed RCEL and the average price target is 7.65 USD. This implies a price increase of 111.33% is expected in the next year compared to the current price of 3.62.
Can you provide the consensus rating for AVITA MEDICAL INC stock?
The consensus rating for AVITA MEDICAL INC (RCEL) is 75.3846 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed AVITA MEDICAL INC (RCEL)?
The number of analysts covering AVITA MEDICAL INC (RCEL) is 13.